![Page 1: NAATC JACIE TALK...Immune effector cells •Any cellular therapy product used to modulate an immune response for therapeutic intent –dendritic cells –natural killer cells –B](https://reader034.vdocuments.mx/reader034/viewer/2022042201/5ea140745ad462367c7a64f5/html5/thumbnails/1.jpg)
Workshop Session
JACIE Inspection Process
Dr Erin Hurst Consultant Haematologist, Newcastle Hospitals
![Page 2: NAATC JACIE TALK...Immune effector cells •Any cellular therapy product used to modulate an immune response for therapeutic intent –dendritic cells –natural killer cells –B](https://reader034.vdocuments.mx/reader034/viewer/2022042201/5ea140745ad462367c7a64f5/html5/thumbnails/2.jpg)
Reflections on Advanced Therapy in NHS – Role of JACIE
Erin Hurst
Consultant Haematologist, NCCC
![Page 3: NAATC JACIE TALK...Immune effector cells •Any cellular therapy product used to modulate an immune response for therapeutic intent –dendritic cells –natural killer cells –B](https://reader034.vdocuments.mx/reader034/viewer/2022042201/5ea140745ad462367c7a64f5/html5/thumbnails/3.jpg)
Introduction
• What is JACIE?
• Immune effector cells [IEC]
• IEC and JACIE
![Page 4: NAATC JACIE TALK...Immune effector cells •Any cellular therapy product used to modulate an immune response for therapeutic intent –dendritic cells –natural killer cells –B](https://reader034.vdocuments.mx/reader034/viewer/2022042201/5ea140745ad462367c7a64f5/html5/thumbnails/4.jpg)
• Joint Accreditation Committee for ISCT and EBMT
– Internationally agreed standards of care for bone marrow transplantation • Clinical • Collection • Processing
• 4 yearly cycle • Peer review • No legal authority
![Page 5: NAATC JACIE TALK...Immune effector cells •Any cellular therapy product used to modulate an immune response for therapeutic intent –dendritic cells –natural killer cells –B](https://reader034.vdocuments.mx/reader034/viewer/2022042201/5ea140745ad462367c7a64f5/html5/thumbnails/5.jpg)
Who Cares?
![Page 6: NAATC JACIE TALK...Immune effector cells •Any cellular therapy product used to modulate an immune response for therapeutic intent –dendritic cells –natural killer cells –B](https://reader034.vdocuments.mx/reader034/viewer/2022042201/5ea140745ad462367c7a64f5/html5/thumbnails/6.jpg)
Who cares? • Demonstrates best practice
• Improves patient outcomes
• Demonstrates quality service
– Patients
– Researchers
– Pharma
– Commissioners
![Page 7: NAATC JACIE TALK...Immune effector cells •Any cellular therapy product used to modulate an immune response for therapeutic intent –dendritic cells –natural killer cells –B](https://reader034.vdocuments.mx/reader034/viewer/2022042201/5ea140745ad462367c7a64f5/html5/thumbnails/7.jpg)
![Page 8: NAATC JACIE TALK...Immune effector cells •Any cellular therapy product used to modulate an immune response for therapeutic intent –dendritic cells –natural killer cells –B](https://reader034.vdocuments.mx/reader034/viewer/2022042201/5ea140745ad462367c7a64f5/html5/thumbnails/8.jpg)
Demonstrating JACIE compliance
• Quality Management system
– What should we do?
– Do we do what we said we would?
– Are we keeping practice up to date?
![Page 9: NAATC JACIE TALK...Immune effector cells •Any cellular therapy product used to modulate an immune response for therapeutic intent –dendritic cells –natural killer cells –B](https://reader034.vdocuments.mx/reader034/viewer/2022042201/5ea140745ad462367c7a64f5/html5/thumbnails/9.jpg)
Demonstrating JACIE standards • Quality Management system
– What should we do? • Policies and procedures • Q pulse
– Do we do what we said we would? • Patient outcome • Audits • Deviations • DATIX • M+M meetings
– Are we keeping practice up to date • Review all policies every 2 years • National policy changes • Clinical trials
![Page 10: NAATC JACIE TALK...Immune effector cells •Any cellular therapy product used to modulate an immune response for therapeutic intent –dendritic cells –natural killer cells –B](https://reader034.vdocuments.mx/reader034/viewer/2022042201/5ea140745ad462367c7a64f5/html5/thumbnails/10.jpg)
JACIE and IEC
• Version 6.01 first standards to include IEC
• Currently version 7 standards
![Page 11: NAATC JACIE TALK...Immune effector cells •Any cellular therapy product used to modulate an immune response for therapeutic intent –dendritic cells –natural killer cells –B](https://reader034.vdocuments.mx/reader034/viewer/2022042201/5ea140745ad462367c7a64f5/html5/thumbnails/11.jpg)
Immune effector cells • Any cellular therapy product used to modulate an
immune response for therapeutic intent – dendritic cells – natural killer cells – B cells – T cells
• Donor lymphocyte infusions • Viral specific T cells e.g. EBV • Chimeric antigen receptor T cells (CAR-T cells)
![Page 12: NAATC JACIE TALK...Immune effector cells •Any cellular therapy product used to modulate an immune response for therapeutic intent –dendritic cells –natural killer cells –B](https://reader034.vdocuments.mx/reader034/viewer/2022042201/5ea140745ad462367c7a64f5/html5/thumbnails/12.jpg)
Chimeric Antigen receptor (CAR)-T cells
https://scienceblog.cancerresearchuk.org/2016/01/19/engineering-a-cancer-fighting-immune-super-soldier/
![Page 13: NAATC JACIE TALK...Immune effector cells •Any cellular therapy product used to modulate an immune response for therapeutic intent –dendritic cells –natural killer cells –B](https://reader034.vdocuments.mx/reader034/viewer/2022042201/5ea140745ad462367c7a64f5/html5/thumbnails/13.jpg)
JACIE JACIE
![Page 14: NAATC JACIE TALK...Immune effector cells •Any cellular therapy product used to modulate an immune response for therapeutic intent –dendritic cells –natural killer cells –B](https://reader034.vdocuments.mx/reader034/viewer/2022042201/5ea140745ad462367c7a64f5/html5/thumbnails/14.jpg)
JACIE IEC standards • 43 specific IEC standards
– Chain of custody
– Toxicity management
• Clinical network
• SOPs
• Staff training
– Quality management system
– Outcome follow up and reporting
![Page 15: NAATC JACIE TALK...Immune effector cells •Any cellular therapy product used to modulate an immune response for therapeutic intent –dendritic cells –natural killer cells –B](https://reader034.vdocuments.mx/reader034/viewer/2022042201/5ea140745ad462367c7a64f5/html5/thumbnails/15.jpg)
NCCC JACIE experience • 43 specific IEC standards
– Chain of custody
– Toxicity management
• Clinical network
• SOPs
• Staff training
– Quality management system
– Outcome follow up and reporting
![Page 16: NAATC JACIE TALK...Immune effector cells •Any cellular therapy product used to modulate an immune response for therapeutic intent –dendritic cells –natural killer cells –B](https://reader034.vdocuments.mx/reader034/viewer/2022042201/5ea140745ad462367c7a64f5/html5/thumbnails/16.jpg)
Clinical network
Consultant Haematologists Consultant
Neurologist
Consultant
intensivists
Middle grade and
junior doctors
Haematology
nurses
ITU nurses Pharmacists
Quality manager
Apheresis team
MDT
Regional / national colleagues
Stem cell Lab
![Page 17: NAATC JACIE TALK...Immune effector cells •Any cellular therapy product used to modulate an immune response for therapeutic intent –dendritic cells –natural killer cells –B](https://reader034.vdocuments.mx/reader034/viewer/2022042201/5ea140745ad462367c7a64f5/html5/thumbnails/17.jpg)
Clinical network Patient
identification
• Consultant Haematologists
• Regional/National colleges
• MDT
CAR-T production
• Apheresis team
• Stem cell lab
Patient management
• ITU
• Neurology
• Haematology
• Nurses
• Pharmacists
![Page 18: NAATC JACIE TALK...Immune effector cells •Any cellular therapy product used to modulate an immune response for therapeutic intent –dendritic cells –natural killer cells –B](https://reader034.vdocuments.mx/reader034/viewer/2022042201/5ea140745ad462367c7a64f5/html5/thumbnails/18.jpg)
NCCC JACIE experience
• SOPs
~ 20 new policies for adult clinical team alone
• Training
• Training
• Training
![Page 19: NAATC JACIE TALK...Immune effector cells •Any cellular therapy product used to modulate an immune response for therapeutic intent –dendritic cells –natural killer cells –B](https://reader034.vdocuments.mx/reader034/viewer/2022042201/5ea140745ad462367c7a64f5/html5/thumbnails/19.jpg)
Standard example
• The Clinical program shall establish and maintain policies relating to the management of toxicities of immune effector cellular therapies, including cytokine release syndrome and central nervous system complications.
![Page 20: NAATC JACIE TALK...Immune effector cells •Any cellular therapy product used to modulate an immune response for therapeutic intent –dendritic cells –natural killer cells –B](https://reader034.vdocuments.mx/reader034/viewer/2022042201/5ea140745ad462367c7a64f5/html5/thumbnails/20.jpg)
Evidence • CRS and CRES management policy
• CRS assessment tool
• CRES assessment tool
• Patient information leaflet
• ITU transfer policy
• ITU and neurology communication pathway
• Pharmacy policy for Tocilizumab administration
• Education session slides
• Electronic policy acknowledgement
![Page 21: NAATC JACIE TALK...Immune effector cells •Any cellular therapy product used to modulate an immune response for therapeutic intent –dendritic cells –natural killer cells –B](https://reader034.vdocuments.mx/reader034/viewer/2022042201/5ea140745ad462367c7a64f5/html5/thumbnails/21.jpg)
JACIE Summary • Internationally agreed set of standards relating to cellular therapy
products • Standards 6.01 first to include immune effector cells [IEC] e.g. CAR-
T cells • In the UK all CAR-T centres must be compliant with the JACIE 6.01
standards • Demonstrating compliance requires a quality management system
and team approach – specific policies outlining how the standards are met – robust evidence to ensure these policies are followed